NCT06556199View on ClinicalTrials.gov

A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions
DRUG

Selinexor

Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.

DRUG

Temozolomide

Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.

DRUG

Anti-PD-1 monoclonal antibody

The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER